The AURA 3 trial was a phase 3 trial to elucidate the efficacy of osimertinib compared with platinum doublet chemotherapy in patients with T790M-positive advanced NSCLC who had disease progression after first-line EGFR-TKI 13. Here, EGFR is linked to non-small cell lung carcinoma.